25 August, 2010
Heart failure is a condition in which the can’t pump enough blood to meet the body’s needs.
Congestive heart failure (CHF) is a chronic cardiovascular disease process and may cause disability and even death. Use of the Type 2 diabetes drug Avandia has been linked to an increased risk of congestive heart failure (CHF) and death. Continue reading Avandia Heart Failure Lawsuit Settlements
Category: Avandia Cardiovascular Risk | Avandia Lawsuit | Avandia Safety | Congestive Heart Failure27 July, 2010
A heart attack is the sudden death heart cells due to inadequate blood flow to part of the heart.
A heart attack occurs when blood supply to an area of the heart is cut off by a clot blocking coronary artery blood flow to the heart. Heart damages caused by heart attack oxygen deprivation can rapidly lead to permanent disability and death. Use of the Type 2 diabetes drug Avandia has been linked to an increased risk of heart attack. Continue reading Avandia Heart Attack Lawsuit
Category: Avandia Cardiovascular Risk | Avandia Side Effects25 July, 2010
A stroke is the sudden death of brain cells due to inadequate blood flow to part of the brain.
A stroke occurs when blood flow to an area of the brain is cut off by a blockage or rupture of a blood vessel to or within the brain. Damage to brain cells caused by stroke-related oxygen deprivation can rapidly lead to permanent disability and death. Use of the Type 2 diabetes drug Avandia has been linked to an increased risk of stroke. Continue reading Avandia Stroke Lawsuit
Category: Avandia Cardiovascular Risk | Avandia Side Effects11 July, 2010
Advisory Committee Briefing Document: Cardiovascular Safety of Rosiglitazone
Prepared by GlaxoSmithKline for the Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee
Meeting on July 13-14, 2010 Continue reading FDA Advisory Committee Briefing Document: Cardiovascular Safety of Avandia
1 July, 2010
Three new studies about Avandia side effects and heart risks were released this week. Two link the diabetes drug to an increased risk of heart attack, stroke or heart failure. The third suggests that taking Avandia may be associated with a lower risk of heart attack, stroke or death than not taking Avandia or Actos, its rival TZD. As the July FDA drug safety meeting approaches and Avandia lawsuit settlements are reported, demands for an Avandia recall are intensifying. Continue reading Cardiac researcher predicts new heart risks warning, but no Avandia recall by FDA
Category: Avandia Cardiovascular Risk | Avandia News | Avandia Recall | Avandia Safety13 June, 2010
The FDA denies suppressing a new study showing that Avandia use increases cardiovascular risks compared to Actos.
A recent study comparing the cardiovascular risks of rival Type 2 diabetes drugs has shown Actos to be safer than Avandia. The study, conducted by government scientists, found that Avandia increased the risk of heart attack, stroke, heart failure and death. Continue reading New study shows Avandia increases heart risks, FDA blocks publication
Category: Avandia Cardiovascular Risk | Avandia News | Avandia Safety8 June, 2010
Amid lawsuit settlements and calls for a recall, researchers claims low-dose Avandia may be safe.
A new study suggests that combination therapy using a low dose of Avandia may help prevent type 2 diabetes without increasing the risk of heart attack and death. Continue reading New study claims low-dose therapy may be safe as Avandia lawsuit settlements announced
Category: Avandia Cardiovascular Risk | Avandia News | Avandia Safety | Avandia Settlements20 May, 2010
GSK is having serious problems recruiting volunteers to participate in a large clinical trial of Avandia.
Two sites in the U.S. recently have withdrawn from the study due to poor enrollment. Several previous studies have linked the diabetes drug to an increased risk of heart attack. In response, Glaxo opened dozens of new Avandia trial sites last month outside the U.S. in developing nations, where participants may not be aware of the safety questions surrounding the diabetes drug. Continue reading Avandia trial: Glaxo having problems recruiting patient volunteers
Category: Avandia Cardiovascular Risk | Avandia News | Avandia Safety24 April, 2010
Avandia safety assessment at July meeting of joint FDA committees to lead to TIDE Trial decision.
When the FDA convenes a joint meeting of its Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory committees in July, the agency will assess the cardiovascular safety of Avandia and decide whether the controversial TIDE… Continue reading Assessment of Avandia Safety at July FDA meeting to lead to TIDE Trial decision
Category: Avandia Cardiovascular Risk | Avandia FDA | Avandia News | Avandia Recall | Avandia Safety | Avandia Senate Report21 April, 2010
An Avandia safety study called the TIDE trial may be suspended by the FDA over Avandia heart attack risks.
Calls for an Avandia recall have been renewed over concerns that the diabetes drug increases heart risks. In February, a critical Senate report on Avandia was released following a two-year Senate Finance Committee investigation… Continue reading FDA may suspend Avandia safety study, could lead to Avandia recall
Category: Avandia Cardiovascular Risk | Avandia FDA | Avandia News | Avandia Recall | Avandia Safety | Avandia Senate Report